Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Fléchon A, Tombal B, Supiot S, Berthold D, Ronchin P, Kacso G, Gravis G, Calabro F, Berdah JF, Hasbini A, Silva M, Thiery-Vuillemin A, Latorzeff I, Mourey L, Laguerre B, Abadie-Lacourtoisie S, Martin E, El Kouri C, Escande A, Rosello A, Magne N, Schlurmann F, Priou F, Chand-Fouche ME, Freixa SV, Jamaluddin M, Rieger I, Bossi A; PEACE-1 investigators. Fizazi K, et al. Among authors: escande a. Lancet. 2022 Apr 30;399(10336):1695-1707. doi: 10.1016/S0140-6736(22)00367-1. Epub 2022 Apr 8. Lancet. 2022. PMID: 35405085 Clinical Trial.
Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1.
Berger F, Marce M, Delaloge S, Hardy-Bessard AC, Bachelot T, Bièche I, Pradines A, De La Motte Rouge T, Canon JL, André F, Arnould L, Clatot F, Lemonnier J, Marques S, Bidard FC; PADA-1 investigators. Berger F, et al. BMJ Open. 2022 Mar 3;12(3):e055821. doi: 10.1136/bmjopen-2021-055821. BMJ Open. 2022. PMID: 35241469 Free PMC article. Clinical Trial.
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.
Bidard FC, Hardy-Bessard AC, Dalenc F, Bachelot T, Pierga JY, de la Motte Rouge T, Sabatier R, Dubot C, Frenel JS, Ferrero JM, Ladoire S, Levy C, Mouret-Reynier MA, Lortholary A, Grenier J, Chakiba C, Stefani L, Plaza JE, Clatot F, Teixeira L, D'Hondt V, Vegas H, Derbel O, Garnier-Tixidre C, Canon JL, Pistilli B, André F, Arnould L, Pradines A, Bièche I, Callens C, Lemonnier J, Berger F, Delaloge S; PADA-1 investigators. Bidard FC, et al. Lancet Oncol. 2022 Nov;23(11):1367-1377. doi: 10.1016/S1470-2045(22)00555-1. Epub 2022 Sep 29. Lancet Oncol. 2022. PMID: 36183733 Clinical Trial.
[Ethical stakes of information in radiation oncology: Thinking the risk and building the therapeutic alliance].
Haaser T, Lahmi L, Osman D, Gesbert C, Cheval V, Constantinides Y, de Crevoisier R, Dejean C, Escande A, Ghannam Y, Lorchel F, Thureau S, Lagrange JL, Durdux C, Huguet F; Commission éthique de la SFRO. Haaser T, et al. Among authors: escande a. Cancer Radiother. 2023 Sep;27(6-7):480-486. doi: 10.1016/j.canrad.2023.06.006. Epub 2023 Aug 10. Cancer Radiother. 2023. PMID: 37573195 Review. French.
Intermediate-risk endometrial cancer treated with adjuvant brachytherapy using single dosimetric planning: long-term outcome and toxicity assessment.
Cordoba A, Hajj Houssein E, Escande A, Scouarnec C, Narducci F, Martinez Gomez C, Leblanc E, Hudry D, Pasquesoone C, Taieb S, Mirabel X, Lartigau EF, Le Tinier F. Cordoba A, et al. Among authors: escande a. Eur J Obstet Gynecol Reprod Biol. 2024 Apr 30;298:23-30. doi: 10.1016/j.ejogrb.2024.04.040. Online ahead of print. Eur J Obstet Gynecol Reprod Biol. 2024. PMID: 38705010
[Characteristics of radiotherapy for adolescents and young adults].
Ollivier L, Laprie A, Jouglar E, Claude L, Martin V, Muracciole X, Padovani L, Supiot S, Escande A. Ollivier L, et al. Among authors: escande a. Cancer Radiother. 2023 Dec;27(8):736-745. doi: 10.1016/j.canrad.2023.08.002. Epub 2023 Oct 26. Cancer Radiother. 2023. PMID: 38652674 Review. French.
Interstitial needles versus intracavitary applicators only for locally advanced cervical cancer: results from real-life dosimetric comparisons.
Cordoba A, Gesta E, Escande A, Noeuveglise A, Cayez R, Halty A, Ladjimi MT, Narducci F, Hudry D, Martinez Gomez C, Cordoba S, Le Deley MC, Barthoulot M, Lartigau EF. Cordoba A, et al. Among authors: escande a. Front Oncol. 2024 Mar 19;14:1347727. doi: 10.3389/fonc.2024.1347727. eCollection 2024. Front Oncol. 2024. PMID: 38567146 Free PMC article.
Role of radiotherapy in the management of rare gynaecological cancers.
Morcet-Delattre R, Espenel S, Tas P, Chargari C, Escande A. Morcet-Delattre R, et al. Among authors: escande a. Cancer Radiother. 2023 Dec;27(8):778-788. doi: 10.1016/j.canrad.2023.08.006. Epub 2023 Nov 2. Cancer Radiother. 2023. PMID: 37925347 Review.
151 results